Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free ICCM Stock Alerts

IceCure Medical (ICCM) Financials

IceCure Medical logo
$3.66 +0.06 (+1.67%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$3.61 -0.05 (-1.37%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for IceCure Medical

Annual Income Statements for IceCure Medical

This table shows IceCure Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.55 -3.73 -9.90 -17 -15 -15 -15
Consolidated Net Income / (Loss)		 -4.55 -3.73 -9.90 -17 -15 -15 -15
Net Income / (Loss) Continuing Operations		 -4.55 -3.73 -9.90 -17 -15 -15 -15
Total Pre-Tax Income 		-4.55 -3.73 -9.90 -17 -15 -15 -15
Total Operating Income		 -4.78 -4.14 -9.72 -17 -16 -16 -15
Total Gross Profit		 0.52 2.44 2.20 1.45 1.30 1.45 1.23
Total Revenue		 1.63 3.87 4.14 3.09 3.23 3.29 3.38
Operating Revenue		 1.63 3.87 4.14 3.09 3.23 3.29 3.38
Total Cost of Revenue		 1.10 1.42 1.94 1.64 1.93 1.84 2.15
Operating Cost of Revenue		 1.10 1.42 1.94 1.64 1.93 1.84 2.15
Total Operating Expenses		 5.31 6.59 12 18 17 17 16
Selling, General & Admin Expense		 1.27 2.78 4.13 5.86 4.17 3.76 4.53
Marketing Expense		 1.04 - 1.92 3.20 4.44 6.30 4.36
Research & Development Expense		 3.00 3.81 5.88 9.12 8.27 7.10 7.43
Total Other Income / (Expense), net		 0.23 0.41 -0.17 -0.24 0.92 0.38 0.04
Other Income / (Expense), net		 0.23 0.41 - -0.24 0.92 0.38 0.04
Basic Earnings per Share		 $0.33 $0.22 $0.35 $0.46 $0.32 $0.30 $0.24
Weighted Average Basic Shares Outstanding		 13.62M 17.13M 28.55M 37.02M 45.64M 50.88M 63.58M
Diluted Earnings per Share		 - - - $0.46 $0.32 $0.30 $0.24
Weighted Average Diluted Shares Outstanding		 - - 35.78M 37.02M 45.64M 50.88M 63.58M
Weighted Average Basic & Diluted Shares Outstanding		 - - 35.78M 45.62M 45.73M 56.57M 73.12M

Quarterly Income Statements for IceCure Medical

No quarterly income statements for IceCure Medical are available.

Annual Cash Flow Statements for IceCure Medical

This table details how cash moves in and out of IceCure Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.22 -2.50 22 -1.61 -13 -2.93 1.22
Net Cash From Operating Activities		 -1.99 -3.69 -13 -14 -13 -13 -15
Net Cash From Continuing Operating Activities		 -1.99 -3.69 -13 -14 -13 -13 -15
Net Income / (Loss) Continuing Operations		 -4.55 -3.73 -9.90 -17 -15 -15 -15
Consolidated Net Income / (Loss)		 -4.55 -3.73 -9.90 -17 -15 -15 -15
Depreciation Expense		 0.03 0.06 0.13 0.25 0.32 0.33 0.30
Non-Cash Adjustments To Reconcile Net Income		 -0.21 -0.30 0.32 2.22 1.26 0.91 1.26
Changes in Operating Assets and Liabilities, net		 2.74 0.28 -3.16 0.21 0.52 1.52 -1.07
Net Cash From Investing Activities		 -0.10 -4.67 3.79 -0.89 -0.68 0.45 -0.04
Net Cash From Continuing Investing Activities		 -0.10 -4.67 3.79 -0.89 -0.68 0.45 -0.04
Purchase of Property, Plant & Equipment		 -0.10 -0.22 -0.53 -0.89 -0.48 -0.07 -0.04
Purchase of Investments		 - - - 0.00 -0.50 -1.37 -5.00
Sale and/or Maturity of Investments		 - - - 0.00 0.00 1.90 5.00
Other Investing Activities, net		 0.00 -4.45 4.33 0.00 0.30 -0.01 0.00
Net Cash From Financing Activities		 3.31 5.86 31 14 0.08 9.19 16
Net Cash From Continuing Financing Activities		 3.31 5.86 31 14 0.08 9.19 16
Repayment of Debt		 - - - - 0.00 0.00 -2.00
Issuance of Debt		 0.00 0.00 - - 0.00 0.00 2.00
Issuance of Common Equity		 3.31 5.85 31 14 0.00 9.19 16
Other Financing Activities, net		 0.00 0.01 0.34 0.00 0.08 0.00 0.30

Quarterly Cash Flow Statements for IceCure Medical

No quarterly cash flow statements for IceCure Medical are available.

Annual Balance Sheets for IceCure Medical

This table presents IceCure Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 10 32 30 16 13 14
Total Current Assets		 9.59 30 28 14 11 13
Cash & Equivalents		 3.50 26 24 11 7.56 8.90
Accounts Receivable		 0.09 0.46 0.08 0.10 0.22 0.33
Inventories, net		 1.06 1.96 2.86 2.28 1.99 2.63
Prepaid Expenses		 0.26 2.29 1.24 0.74 0.98 0.75
Plant, Property, & Equipment, net		 0.31 0.71 1.36 1.51 1.25 0.99
Total Noncurrent Assets		 0.34 1.25 0.70 0.71 0.57 0.29
Other Noncurrent Operating Assets		 0.04 0.33 0.70 0.71 0.57 0.29
Total Liabilities & Shareholders' Equity		 10 32 30 16 13 14
Total Liabilities		 4.59 5.32 4.77 4.25 5.68 4.84
Total Current Liabilities		 3.71 4.02 4.34 3.87 5.51 4.82
Accounts Payable		 0.65 0.88 0.71 0.50 1.23 0.86
Current Employee Benefit Liabilities		 - - - 3.15 2.76 2.66
Other Current Liabilities		 3.07 3.14 3.62 0.22 1.53 1.30
Total Noncurrent Liabilities		 0.88 1.30 0.43 0.38 0.16 0.01
Long-Term Debt		 0.76 0.62 - - 0.16 0.01
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.65 27 25 12 6.90 9.05
Total Preferred & Common Equity		 5.65 27 25 12 6.90 9.05
Total Common Equity		 5.65 27 25 12 6.90 9.05
Common Stock		 54 85 101 102 112 129
Retained Earnings		 -49 -58 -75 -90 -105 -120

Quarterly Balance Sheets for IceCure Medical

No quarterly balance sheets for IceCure Medical are available.

Annual Metrics And Ratios for IceCure Medical

This table displays calculated financial ratios and metrics derived from IceCure Medical's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 35,780,335.00 45,623,434.00 45,729,684.00 113,137,998.00 73,122,293.00
DEI Adjusted Shares Outstanding		 0.00 0.00 35,780,335.00 1,520,781.00 1,524,323.00 113,137,998.00 73,122,293.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.28 -11.16 -9.61 -0.14 -0.21
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 6.98% -25.45% 4.67% 1.92% 2.67%
EBITDA Growth		 0.00% 0.00% -161.71% -74.33% 14.35% -4.59% 1.49%
EBIT Growth		 0.00% 0.00% -160.70% -74.60% 13.70% -4.55% 1.70%
NOPAT Growth		 0.00% 0.00% -134.77% -72.14% 6.95% -0.77% 3.84%
Net Income Growth		 0.00% 0.00% -165.28% -71.58% 13.70% -4.55% 1.70%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -30.43% -6.25% -20.00%
Operating Cash Flow Growth		 0.00% 0.00% -241.60% -13.38% 12.19% -0.10% -16.01%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% -90.53% 6.16% 10.94% -19.72%
Invested Capital Growth		 0.00% 0.00% -31.83% -24.96% -24.95% -145.59% 133.27%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 32.21% 63.19% 53.04% 46.84% 40.26% 44.09% 36.28%
EBITDA Margin		 -277.75% -94.80% -231.92% -542.30% -443.76% -455.36% -436.87%
Operating Margin		 -294.04% -107.08% -234.99% -542.59% -482.38% -476.94% -446.70%
EBIT Margin		 -279.72% -96.43% -234.99% -550.34% -453.76% -465.45% -445.61%
Profit (Net Income) Margin		 -279.72% -96.43% -239.13% -550.34% -453.76% -465.45% -445.61%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 101.76% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -101.09% -282.26% -684.82% -849.16% -3,668.51% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -71.22% -260.03% -663.33% -827.75% -3,621.61% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 35.05% 221.57% 620.00% 771.19% 3,507.81% 0.00%
Return on Equity (ROE)		 0.00% -66.04% -60.69% -64.83% -77.97% -160.70% -188.78%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -244.40% -656.30% -820.65% 0.00% -6,727.43%
Operating Return on Assets (OROA)		 0.00% -36.43% -45.74% -54.36% -62.89% -105.69% -113.79%
Return on Assets (ROA)		 0.00% -36.43% -46.54% -54.36% -62.89% -105.69% -113.79%
Return on Common Equity (ROCE)		 0.00% -66.04% -60.69% -64.83% -77.97% -160.70% -188.78%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -66.04% -36.71% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.35 -2.90 -6.81 -12 -11 -11 -11
NOPAT Margin		 -205.83% -74.96% -164.49% -379.82% -337.66% -333.86% -312.69%
Net Nonoperating Expense Percent (NNEP)		 0.00% -29.88% -22.23% -21.49% -21.41% -46.91% -55.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -46.09% -89.64% -155.58% -116.57%
Cost of Revenue to Revenue		 67.79% 36.81% 46.96% 53.16% 59.74% 55.91% 63.72%
SG&A Expenses to Revenue		 78.18% 71.79% 99.69% 189.85% 129.02% 114.10% 134.03%
R&D to Revenue		 184.45% 98.47% 142.03% 295.72% 256.21% 215.62% 219.98%
Operating Expenses to Revenue		 326.24% 170.27% 288.04% 589.43% 522.64% 521.03% 482.98%
Earnings before Interest and Taxes (EBIT)		 -4.55 -3.73 -9.72 -17 -15 -15 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.52 -3.67 -9.60 -17 -14 -15 -15
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 2.04 3.75 6.82 3.81
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 2.04 3.75 6.82 3.81
Price to Revenue (P/Rev)		 0.00 0.00 0.00 16.82 14.14 14.30 10.21
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 19.03 31.43 0.00 153.47
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 9.05 10.72 12.05 7.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.13 0.02 0.00 0.00 0.02 0.00
Long-Term Debt to Equity		 0.00 0.13 0.02 0.00 0.00 0.02 0.00
Financial Leverage		 0.00 -0.49 -0.85 -0.93 -0.93 -0.97 -1.02
Leverage Ratio		 0.00 1.81 1.30 1.19 1.24 1.52 1.66
Compound Leverage Factor		 0.00 1.81 1.33 1.19 1.24 1.52 1.66
Debt to Total Capital		 0.00% 11.85% 2.24% 0.00% 0.00% 2.28% 0.14%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 11.85% 2.24% 0.00% 0.00% 2.28% 0.14%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 88.15% 97.76% 100.00% 100.00% 97.72% 99.86%
Debt to EBITDA		 0.00 -0.21 -0.06 0.00 0.00 -0.01 0.00
Net Debt to EBITDA		 0.00 0.75 2.61 0.00 0.00 0.49 0.60
Long-Term Debt to EBITDA		 0.00 -0.21 -0.06 0.00 0.00 -0.01 0.00
Debt to NOPAT		 0.00 -0.26 -0.09 0.00 0.00 -0.01 0.00
Net Debt to NOPAT		 0.00 0.95 3.67 0.00 0.00 0.67 0.84
Long-Term Debt to NOPAT		 0.00 -0.26 -0.09 0.00 0.00 -0.01 0.00
Altman Z-Score		 0.00 0.00 0.00 2.23 -3.23 -10.01 -10.52
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 2.58 7.54 6.49 3.66 1.95 2.61
Quick Ratio		 0.00 0.97 6.49 5.47 2.88 1.41 1.91
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -5.89 -11 -11 -9.38 -11
Operating Cash Flow to CapEx		 -1,931.07% -1,654.71% -2,364.92% -1,604.04% -2,614.58% -17,694.37% -40,483.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.38 0.19 0.10 0.14 0.23 0.26
Accounts Receivable Turnover		 0.00 41.15 15.05 11.55 35.68 20.31 12.24
Inventory Turnover		 0.00 1.34 1.29 0.68 0.75 0.86 0.93
Fixed Asset Turnover		 0.00 12.60 8.11 2.98 2.25 2.38 3.01
Accounts Payable Turnover		 0.00 2.21 2.55 2.06 3.17 2.12 2.06
Days Sales Outstanding (DSO)		 0.00 8.87 24.26 31.59 10.23 17.97 29.81
Days Inventory Outstanding (DIO)		 0.00 272.72 283.57 535.48 485.53 422.82 391.02
Days Payable Outstanding (DPO)		 0.00 165.33 143.33 177.49 115.04 171.99 177.58
Cash Conversion Cycle (CCC)		 0.00 116.27 164.49 389.58 380.72 268.81 243.25
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 2.87 1.96 1.47 1.10 -0.50 0.17
Invested Capital Turnover		 0.00 1.35 1.72 1.80 2.51 10.99 -20.17
Increase / (Decrease) in Invested Capital		 0.00 0.00 -0.91 -0.49 -0.37 -1.60 0.67
Enterprise Value (EV)		 0.00 0.00 0.00 28 35 40 26
Market Capitalization		 0.00 0.00 0.00 52 46 47 35
Book Value per Share		 $0.00 $0.33 $0.94 $0.71 $0.27 $0.15 $0.16
Tangible Book Value per Share		 $0.00 $0.33 $0.94 $0.71 $0.27 $0.15 $0.16
Total Capital		 0.00 6.41 28 25 12 7.06 9.06
Total Debt		 0.00 0.76 0.62 0.00 0.00 0.16 0.01
Total Long-Term Debt		 0.00 0.76 0.62 0.00 0.00 0.16 0.01
Net Debt		 0.00 -2.74 -25 -24 -11 -7.40 -8.88
Capital Expenditures (CapEx)		 0.10 0.22 0.53 0.89 0.48 0.07 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 2.37 0.68 -0.16 -0.75 -2.32 -1.12
Debt-free Net Working Capital (DFNWC)		 0.00 5.88 26 24 10 5.24 7.78
Net Working Capital (NWC)		 0.00 5.88 26 24 10 5.24 7.78
Net Nonoperating Expense (NNE)		 1.20 0.83 3.09 5.26 3.75 4.33 4.49
Net Nonoperating Obligations (NNO)		 0.00 -2.78 -25 -24 -11 -7.40 -8.88
Total Depreciation and Amortization (D&A)		 0.03 0.06 0.13 0.25 0.32 0.33 0.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 61.35% 16.46% -5.22% -23.20% -70.62% -33.03%
Debt-free Net Working Capital to Revenue		 0.00% 151.89% 635.62% 771.28% 319.39% 159.22% 230.28%
Net Working Capital to Revenue		 0.00% 151.89% 635.62% 771.28% 319.39% 159.22% 230.28%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.35 $13.80 $9.60 $0.00 $7.20
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 28.55M 1.23M 1.52M 0.00 2.12M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $7.20
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 35.78M 1.52M 1.52M 0.00 2.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 35.78M 1.52M 1.52M 0.00 2.44M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.35 -2.90 -6.81 -12 -11 -11 -11
Normalized NOPAT Margin		 -205.83% -74.96% -164.49% -379.82% -337.66% -333.86% -312.69%
Pre Tax Income Margin		 -279.72% -96.43% -239.13% -550.34% -453.76% -465.45% -445.61%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for IceCure Medical

No quarterly metrics and ratios for IceCure Medical are available.


Financials Breakdown Chart

IceCure Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, IceCure Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

IceCure Medical's net income appears to be on an upward trend, with a most recent value of -$15.06 million in 2025, rising from -$4.55 million in 2019. The previous period was -$15.32 million in 2024. See IceCure Medical's forecast for analyst expectations on what's next for the company.

IceCure Medical's total operating income in 2025 was -$15.09 million, based on the following breakdown:
  • Total Gross Profit: $1.23 million
  • Total Operating Expenses: $16.32 million

Over the last 6 years, IceCure Medical's total revenue changed from $1.63 million in 2019 to $3.38 million in 2025, a change of 107.7%.

IceCure Medical's total liabilities were at $4.84 million at the end of 2025, a 14.8% decrease from 2024, and a 5.4% increase since 2020.

In the past 5 years, IceCure Medical's cash and equivalents has ranged from $3.50 million in 2020 to $25.62 million in 2021, and is currently $8.90 million as of their latest financial filing in 2025.

Over the last 6 years, IceCure Medical's book value per share changed from 0.00 in 2019 to 0.16 in 2025, a change of 16.0%.


Related Companies

Financial statements for NASDAQ:ICCM last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel